



Contact: Wen-Tien Chen
Location: Stony Brook, NY 11790
Email: wentien@vitatex.com
Tel: 631-444-8482
Website: www.vitatex.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program
 (NIH-CAP)

Company Profile

Industry Sector:

Clinical Diagnostics and Biomedical Research Products.

Company Overview:

Vitatex is a diagnostics company focused on developing and commercializing proprietary rare cell enrichment (RCE) technologies for clinical circulating tumor cell (CTC) detection and CTC drug response (CDR) blood tests. These tests will help determine if a patient has aggressive cancer and provide a non-invasive, real-time means of therapy selection during treatment and management of the disease.

Target Market(s):

We address the academic and biopharma clinical research market with research use only (RUO) products, antibody markers that augment progenitor cell and CTC assays, and services to cancer research centers, biotech and pharmaceuticals.

We are seeking one or more partners to address the clinical market with IVD products to help determine a better treatment than currently available lab tests for individual cancer patients.

Key Value Drivers

Technology*:

Vitatex's rare cell enrichment (RCE) technologies use cellular protein-coated surfaces to capture and recover specific rare cells in blood, including circulating tumor cells (CTCs), endothelial, fetal and immune cells.

Competitive Advantage:

Vitatex's RCE detection products are highly sensitive and specific for tumor progenitor (stem) and immune cells. The products include inexpensive, disposable blood collection / culture devices that recover a much higher percentage of the rare cells than current methods. The cells are captured alive and can be cultured, sorted / counted by flow cytometry and microscopy, and analyzed for drug response or specific mutations.

Plan & Strategy:

We are raising funds to support manufacturing and perform proof-of-concept clinical studies. Our goal is to partner with established research product and medical device companies to complete our clinical trials and broaden our marketing and distribution capabilities.

*Technology funded by the NCI ([5R44CA140047-03](#)) and being commercialized under the NIH-CAP

Management

Leadership:

- **Wen-Tien Chen**, PhD, President & Chief Scientific Officer – 27 years of experience with NIH funded academic and small business research; the inventor of Cell Adhesion Matrix (CAM) RCE technology and tumor invasion biomarkers
- **Lee Chen**, Vice President, Operations – Directed operations of two successful startups
- **Qiang Zhao**, MD, Director, Medical Research – 10 years of experience with CTC research
- **Huan Dong**, PhD, Director, Product Research – Leads the development of new CTC detection reagents and tools
- **Che Chen**, Director, Product Development – Leads design and manufacture of Vita-Cap™ and Vita-Assay™ products.

Board of Directors: Wen-Tien Chen, David Hsu and Lee Chen.

Scientific Advisory Board:

- **Michael L. Pearl**, M.D. & **Timothy Yeatman**, M.D. – Advice on clinical utility of CTC detection assays
- **Marc G. Golightly**, Ph.D. – Advice on flow cytometry and clinical immunology.

Product Pipeline

		2012	2013	2014	2015	2016 & beyond
Tools (RUO)	Vita-Assay™ scalable	xxxxxxx				
	Vita-Cap™ scalable		xxxxxxx			
	Progenitor cell kit		xxxxxxx			
	CTC detection kits			xxxxxxx		
	ovarian cancer				xxxxxxx	
	pancreatic cancer				xxxxxxx	
	prostate cancer				xxxxxxx	
breast cancer					xxxxxxx	
lung cancer						xxxxxxx
colorectal cancer						xxxxxxx
Services (CRS)	CTC isolation	xxxxxxx				
	CTC counting	xxxxxxx				
In Vitro Diagnostics (IVD)	IVD launch to determine treatment of ovarian cancer					xxxxxxx